This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Van de Werf, F. Articles by Collen, D. Search for Related Content PubMed PubMed Citation Articles by Van de Werf, F. Articles by Collen, D.

Circulation, Vol 74, 1066-1070, Copyright © 1986 by American Heart Association

ARTICLES

Coronary thrombolysis with recombinant single-chain urokinase-type plasminogen activator in patients with acute myocardial infarction

F Van de Werf, J Vanhaecke, H de Geest, M Verstraete and D Collen

Seventeen patients with acute transmural myocardial infarction and angiographically confirmed complete coronary occlusion were treated with heparin combined with intravenous single-chain urokinase-type plasminogen activator (scu-PA), obtained by expression of the cDNA encoding mature human scu-PA in Escherichia coli. In eight patients, recombinant scu-PA (rscu-PA) was given as a 10 mg bolus followed by 30 mg over 1 hr. Recanalization was obtained in six patients, but with persistent delayed opacification of the vessel in four of these patients. During infusion, a plateau level of rscu-PA antigen in plasma of 3.4 micrograms/ml (median value, range 1.4 to 5.5) was reached. At the end of the infusion the alpha 2-antiplasmin level had decreased to 54% (median, range 22% to 82%) of the preinfusion level, the fibrinogen level to 89% (median, range 26% to 101%), and fibrinogen degradation products (FDPs) to 20 micrograms/ml (median, range 8 to 387). In nine patients, rscu-PA was administered as a 10 mg bolus followed by 60 mg over 1 hr. This resulted in recanalization with normal distal filling of the vessel in seven patients, within 46 +/- 17 min (mean +/- SD). During infusion the concentration of rscu-PA in plasma increased to a median value of 7.4 micrograms/ml (range 4.0 to 13.3). At the end of the infusion the alpha 2-antiplasmin level was 22% of baseline (range 5% to 47%), the fibrinogen level 45% (range 4% to 94%), and the concentration of FDPs 87 micrograms/ml (range 6 to 1034). No significant bleeding or short-term side effects were observed.(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				H. L. Dauerman, D. E. Cutlip, and F. W. Sellke Intracoronary Thrombolysis in the Treatment of Graft Closure Immediately After CABG Ann. Thorac. Surg., July 1, 1996; 62(1): 280 - 283. [Abstract] [Full Text]

				D. W. Krichbaum and D. A. Trivedi Thrombolytic Therapy in Acute Myocardial Infarction Journal of Pharmacy Practice, January 1, 1990; 3(5): 332 - 348. [PDF]

				E Haber, T Quertermous, G. Matsueda, and M. Runge Innovative approaches to plasminogen activator therapy Science, January 6, 1989; 243(4887): 51 - 56. [Abstract] [PDF]

				E. J. Harris JR and J. M. Porter Thrombolytic Therapy and Modern Vascular Surgery: An Overview Perspectives in Vascular Surgery and Endovascular Therapy, January 1, 1989; 2(2): 40 - 63. [PDF]